NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free CLGN Stock Alerts $5.39 +0.16 (+3.06%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.25▼$5.4750-Day Range$4.71▼$5.8052-Week Range$4.22▼$8.90Volume2,648 shsAverage Volume9,068 shsMarket Capitalization$61.72 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get CollPlant Biotechnologies alerts: Email Address CollPlant Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.1% Upside$11.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.11 to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector682nd out of 938 stocksBiotechnology Industry30th out of 47 stocks 3.5 Analyst's Opinion Consensus RatingCollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, CollPlant Biotechnologies has a forecasted upside of 104.1% from its current price of $5.39.Amount of Analyst CoverageCollPlant Biotechnologies has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently decreased by 13.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLGN. Previous Next 1.9 News and Social Media Coverage News SentimentCollPlant Biotechnologies has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CollPlant Biotechnologies this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CollPlant Biotechnologies are expected to decrease in the coming year, from $0.11 to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About CollPlant Biotechnologies Stock (NASDAQ:CLGN)CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.Read More CLGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLGN Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comCollPlant Biotechnologies (CLGN) Scheduled to Post Quarterly Earnings on ThursdayMarch 26, 2024 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!February 15, 2024 | finance.yahoo.comCollPlant Issues Letter to ShareholdersFebruary 15, 2024 | prnewswire.comCollPlant Issues Letter to ShareholdersFebruary 13, 2024 | au.finance.yahoo.comCOLLPLANT BIOTECH. IS-,01 (CPT.MU)January 8, 2024 | finance.yahoo.comCollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, CaliforniaJanuary 2, 2024 | finance.yahoo.comCollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast ImplantsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!December 2, 2023 | benzinga.comCollPlant Biotechnologies Stock (NASDAQ:CLGN), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call TranscriptNovember 29, 2023 | benzinga.comRecap: CollPlant Biotechnologies Q3 EarningsNovember 29, 2023 | msn.comCollPlant Biotechnologies Non-GAAP EPS of -$0.35November 29, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Third Quarter Financial Results for 2023November 9, 2023 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONNovember 3, 2023 | finance.yahoo.comWill CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?November 1, 2023 | msn.comCollPlant says patent granted in U.S. for photocurable dermal fillerNovember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal FillerOctober 5, 2023 | finance.yahoo.comShareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years agoSeptember 21, 2023 | finance.yahoo.comCollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability InitiativeSeptember 5, 2023 | finance.yahoo.comCollPlant to Present at the H.C. Wainwright Annual Growth ConferenceAugust 27, 2023 | finance.yahoo.comResults: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New ForecastsAugust 26, 2023 | finance.yahoo.comInvestors Don't See Light At End Of CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) TunnelAugust 25, 2023 | finance.yahoo.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Call TranscriptAugust 25, 2023 | markets.businessinsider.comCollplant Holdings (CLGN) Gets a Buy from H.C. WainwrightAugust 24, 2023 | seekingalpha.comCollPlant Biotechnologies Non-GAAP EPS of $0.52, revenue of $10.2M beats by $4.86MAugust 24, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 MillionSee More Headlines Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/24/2023Today3/29/2024Next Earnings (Confirmed)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CLGN CUSIPN/A CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees73Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+104.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E Ratio49.00 P/E GrowthN/ANet Income$-16,920,000.00 Net Margins-62.80% Pretax Margin-62.80% Return on Equity-20.61% Return on Assets-17.64% Debt Debt-to-Equity RatioN/A Current Ratio11.85 Quick Ratio11.28 Sales & Book Value Annual Sales$300,000.00 Price / Sales205.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book1.85Miscellaneous Outstanding Shares11,450,000Free Float10,354,000Market Cap$61.72 million OptionableOptionable Beta0.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Yehiel Tal (Age 72)CEO & Director Comp: $865kMr. Eran Rotem CPA (Age 56)Deputy CEO & CFO Comp: $651kProf. Oded Shoseyov (Age 68)Founder & Chief Scientist Comp: $384kMr. Oren Fahimipoor (Age 42)Vice President of Operations Ms. Hadas Dreiher Horowitz (Age 47)Vice President of Human Resources Dr. Elana Gazal (Age 49)Vice President of Research & Development More ExecutivesKey CompetitorsVicarious SurgicalNYSE:RBOTReWalk RoboticsNASDAQ:LFWDMilestone ScientificNYSE:MLSSEnvoy MedicalNASDAQ:COCHNutribandNASDAQ:NTRBView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 1,700 shares on 2/15/2024Ownership: 0.000%Roumell Asset Management LLCSold 145,270 shares on 2/14/2024Ownership: 3.901%Benjamin F. Edwards & Company Inc.Bought 5,100 shares on 2/6/2024Ownership: 0.452%Simplex Trading LLCSold 100 shares on 2/2/2024Ownership: 0.000%Villere ST Denis J & Co. LLCBought 61,120 shares on 1/25/2024Ownership: 3.258%View All Institutional Transactions CLGN Stock Analysis - Frequently Asked Questions Should I buy or sell CollPlant Biotechnologies stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLGN shares. View CLGN analyst ratings or view top-rated stocks. What is CollPlant Biotechnologies' stock price target for 2024? 1 brokerages have issued 12-month target prices for CollPlant Biotechnologies' shares. Their CLGN share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price. View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts. How have CLGN shares performed in 2024? CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN shares have decreased by 15.6% and is now trading at $5.39. View the best growth stocks for 2024 here. Are investors shorting CollPlant Biotechnologies? CollPlant Biotechnologies saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 8,100 shares, a decline of 13.8% from the February 29th total of 9,400 shares. Based on an average trading volume of 11,400 shares, the short-interest ratio is currently 0.7 days. Approximately 0.1% of the company's shares are sold short. View CollPlant Biotechnologies' Short Interest. When is CollPlant Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our CLGN earnings forecast. How can I listen to CollPlant Biotechnologies' earnings call? CollPlant Biotechnologies will be holding an earnings conference call on Thursday, April 4th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) announced its quarterly earnings data on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.83. The firm had revenue of $10.18 million for the quarter, compared to the consensus estimate of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the company earned ($0.39) EPS. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.22%), Roumell Asset Management LLC (3.90%), Villere ST Denis J & Co. LLC (3.26%), Benjamin F. Edwards & Company Inc. (0.45%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLGN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.